Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

The research grant aims to diversify Friedreich ataxia treatments, addressing challenges in trial design and therapeutic strategies for this condition.

Researchers to Assess Gene Editing Technology for Friedreich Ataxia Following MDA, FARA Collaboration

Videos

Neurology News Network. for the week ending April 20, 2024. [WATCH TIME: 3 minutes]

Lecanemab ARIA Rates Unaffected by Centiloid Level, AB-1005 Meets Primary End Point, Fremanezumab Safe in Obese Patients With Migraine

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 19, 2024. 

NeurologyLive® Friday 5 — April 19, 2024

Patients experienced improvements in ON/OFF time and motor function, with favorable tolerability, paving the way for a phase 2 trial.

Parkinson Gene Therapy AB-1005 Continues to Show Promising Results at 18 Months

, has been with the team since October 2019. Follow him on Twitter 

Chief of the Division of MS and Neuroimmunology at UConn Health.

The chief of the Division of MS and Neuroimmunology at UConn Health talked about the unevenly distributed progress in multiple sclerosis care, impacting minority populations who often face worse disease outcomes. [WATCH TIME: 6 minutes]

Advancing MS Care for Minority Populations Using the VISIBL-MS Bilingual Framework: Jaime Imitola, MD

Dermatology resident, University Hospitals.

A trio of experts from university hospitals discussed a study that aimed to uncover the prevalence and associations of limb swelling in patients with Dravet syndrome in hopes of improving care. [WATCH TIME: 5 minutes]

Investigating Limb Swelling in Patients With Dravet Syndrome: Mandy Alhajj, DO, James Dolbow, DO & Neel Fotedar, MD

The executive vice president of research at National MS Society talked about the Dystel Prize which is presented at AAN to a recognized individual who promotes further advancements in understanding and treating MS. [WATCH TIME: 3 minutes]

Recognizing Excellence in Multiple Sclerosis Research, the Dystel Prize: Bruce Bebo, PhD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

AAN 2024

MDA 2024

ACTRIMS 2024

Treating NMOSD: What's Next?

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Slideshows

Seven new drugs were approved for treatment of neurological disorders, including Parkinson disease, multiple sclerosis, and amyotrophic lateral sclerosis.

Clinical

SUP-22-NRD0184 - /clinical/movement-disorders

EMD-22-NRD0193 - /clinical/multiple-sclerosis

FDA Drug and Biologic Approvals for Neurology: 2017 Midyear Review